Live news , top stories, corporate news, company news, sector news, economy news, results analysis news, ceo interviews, fund manager interview, advisor interview, market news, bazaar talk, hot stocks news, ipo news, commodities news, mutual fund news, insurance news, news wire
22 October, 2018 19:59 IST
Alembic Pharma gets USFDA tentative approval for Ticagrelor Tablets
Source: IRIS | 12 Jul, 2018, 10.40AM
Comments  |  Post Comment

Alembic Pharmaceuticals today announced that the company has received tentative approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Ticagrelor Tablets, 90 mg.

The tentatively approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Brilinta Tablets, 90 rng, of Astrazeneca Pharmaceuticals LP. Ticagrelor tablets are indicated to reduce the rate of cardiovascular death, myocardial infarction, and stroke in patients with acute coronary syndrome (ACS) or a history of myocardial infarction (Ml).

Ticagrelor Tablets, 90 mg have an estimated market size of USD 625 million for twelve months ending December 2017 according to IQVIA.

Alembic now has a total of 75 ANDA approvals (65 final approvals and 10 tentative approvals) from USFDA.

Shares of the company gained Rs 5.75, or 1.08%, to trade at Rs 536.65. The total volume of shares traded was 678 at the BSE (10.27 a.m., Thursday).



Alembic Pharmaceuticals Limited   (Q,N,C,F)*

Comments Post comment 
 Post Comment
Name Email
Comment
Security Code type    into this box
Related Articles
Biocon, Mylan announce positive CHMP Opinion for Ogivri - 22-Oct-2018 10:28
Lupin announces positive CHMP opinion for NaMuscla - 22-Oct-2018 09:51
Tejas Networks bags Rs 1.11 bn order from Sterlite Technologies - 22-Oct-2018 09:45
Alembic Pharma' JV completes USFDA inspection of Karakhadi unit - 22-Oct-2018 09:41
Home  |   Shares  |   F&O  |   Mutual Funds  |   Loans  |   Insurance  |   News Centre
Wealth Tracker  |   Newsletters  |   Tax Corner  |   NRI Centre  |   Advertise
© All rights reserved. IRIS Business Services Limited
A Disclaimer